

State of the Nation Report 2026



NNHLA

National Non-Hodgkin
Lymphoma Audit

Summary of results for people diagnosed with non-Hodgkin lymphoma (NHL) between 1 January 2023 and 31 December 2023 in England and 1 January 2024 and 31 December 2024 in Wales.

Diagnosis and treatment pathway

Diagnoses per year

England
15,911 diagnosed in 2023

Wales
707 diagnosed in 2024

Grade of lymphoma

England 2023
high-grade 50%
low-grade 49%
not classified 1%

Wales 2024
high-grade 47%
low-grade 52%
not classified 1%

MDT discussion within 4 weeks of diagnosis, where recorded

England 2023
all patients 61%,
high-grade 66%,
low-grade 55%

No data on MDT discussion was provided for Wales

Seen by Clinical Nurse Specialist (CNS), where recorded



England 2023 85%
Wales 2024 95%

43% data completeness in England
80% data completeness in Wales

69
years

Mean age at diagnosis for both England & Wales

Emergency presentation

England 2023 29%
Wales 2024 29%



Systemic Anti-Cancer Therapy (SACT)



England 2023

56%


Wales 2024

62%

Proportion of people diagnosed with high-grade lymphoma, who receive SACT within 62 days of referral

Median Time (IQR*)

*Interquartile range



Time of seeing a haematologist not available for Wales

Treatment

England 2023

Severe acute toxicity

47%

Proportion of people diagnosed with DLBCL experiencing severe acute toxicity within 8 weeks of completing SACT.

End date for 1st line chemotherapy was not provided for Wales so this indicator could not be measured.

England 2023

Timing of Radiotherapy delivery

32%

Proportion of people with high-grade lymphoma whose consolidation radiotherapy started within 8 weeks of end of first line SACT.

End date for 1st line chemotherapy was not provided for Wales so this indicator could not be measured.

Radiotherapy

Proportion of people with NHL receiving radiotherapy within one year of diagnosis

England 2023

12%

IQR: 8-15%

Wales 2024

5%

IQR: 0-7%

England 2023

Trial Participation


less than 3%

Proportion of people with NHL who were recorded as having received an episode of care that was delivered as part of a clinical trial**

**Note 75% data missing. No data on trial participation for Wales was available


Survival

One-year survival outcomes



Two-year survival outcomes***

***Not available for Wales due to insufficient follow up period



Data completeness

